MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
6.83
+0.04
+0.59%
After Hours: 6.83 0 0.00% 19:30 10/02 EDT
OPEN
6.89
PREV CLOSE
6.79
HIGH
7.00
LOW
6.74
VOLUME
587.65K
TURNOVER
--
52 WEEK HIGH
14.53
52 WEEK LOW
2.710
MARKET CAP
333.92M
P/E (TTM)
-2.0622
1D
5D
1M
3M
1Y
5Y
1D
Artiva Biotherapeutics Price Target Maintained With a $40.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Benzinga · 1d ago
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Barchart · 1d ago
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Artiva Biotherapeutics, Inc. (ARTV)
TipRanks · 1d ago
Artiva Biosciences: Buy Rating Reiterated on Strong AlloNK Sjögren’s Data and Favorable Safety, Price Target Maintained at $35
TipRanks · 1d ago
Artiva updates safety, translational data for AlloNK with rituximab
TipRanks · 2d ago
Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris
Benzinga · 2d ago
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Barchart · 2d ago
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.